May 9, 2023 News by Patricia Inacio, PhD Neurologist Robert Lisak named 2023 Giant of Multiple Sclerosis Neurologist Robert Lisak, MD, has been named a 2023 Giant of Multiple Sclerosis for his work in understanding the mechanisms of multiple sclerosis (MS) and improving care for people with the condition. Lisak, MD, a professor of neurology and former chair of the Wayne State University Department of Neurology,…
March 28, 2018 News by Larry Luxner Ocrevus a Year After Approval: Views of Some MS Experts A year after U.S. regulators approved Genentech’sĀ Ocrevus (ocrelizumab)Ā as the first treatment for both the relapsing and progressive forms of multiple sclerosis, a prominent neurologist involved in the Phase 3 clinical trials that led to its authorization says it has been beneficial for some MS patients. But itās simply…
June 2, 2017 News by Patricia Silva, PhD #CMSC17 – Ocrevus, Progressive MS and Other Research Highlights: An Interview with CMSC’s Robert Lisak The recent annual meeting of theĀ Consortium of Multiple Sclerosis Centers (CMSC)Ā brought researchers and healthcare professionals to New Orleans to discuss advances ā and obstacles to advances ā in multiple sclerosis (MS) research. Clinical trials, preclinical studies, basic research, and health interventions were amongĀ the May meeting’s focus. Multiple Sclerosis News…
April 19, 2017 News by Patricia Silva, PhD Are Ocrevus and Rituxan Similar? Neurologists Respond to Patients’ Concerns While manyĀ multiple sclerosis patients celebrated the recent approval of Ocrevus (ocrelizumab), others argued that the drug is largelyĀ a rebranded version ofĀ rituximab. Rituximab ā sold as Rituxan for indications like non-Hodgkin’s lymphoma,Ā chronic lymphocytic leukemia, andĀ rheumatoid arthritis ā is used off-label to treat relapsing MS. In online forums and social media,…
April 4, 2017 News by Patricia Silva, PhD Transcript of Interview with Dr. Robert Lisak, a Neurologist and MS Expert, About Ocrevus Here is a transcript of the Multiple Sclerosis News Today interview about Ocrevus (ocrelizumab) with Dr. Robert Lisak of the Consortium of Multiple Sclerosis Centers (CMSC). Lisak, a professor of neurology and of immunology and microbiology at Wayne State University School of Medicine, is aĀ former…
April 4, 2017 News by Patricia Silva, PhD Ocrevus Holds Promise, But Needs to Prove Itself in ‘Long Term,’ Says Dr. Robert Lisak with CMSC Interest inĀ Ocrevus (ocrelizumab), the first FDA-approved treatment for bothĀ relapsing and primary progressive multiple sclerosis, isĀ running high among patients and the organization representing them ā as, arguably, are expectations ofĀ its use. But how do physicians involved in MS care view the newcomer? Dr. Robert Lisak (Photo courtesy…